Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter double-blind randomized trial of Metvix photodynamic therapy for multiple actinic keratoses on the face or scalp
2005-005015-13Phase 3Completed
- Sponsor
- Photocure
- Start
- Dec 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing Metvix PDT with Vehicle PDT (2 arms). Primary endpoint: Patient complete response rate at 3 months. Started Dec 2005; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2005-005015-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005015-13.